Since retiring from Aventis in 2002, Dr. Franz Jakob Hock has leveraged his experience as a freelance consultant specializing in Safety Pharmacology. Dr. Hock was a research scientist at Hoechst, Hoechst Marion Roussel and Aventis from 1976 – 2002. He lectured for several years at the University of Kassel und the Technical University of Darmstadt. Currently he is a member of the Task Force General/Safety Pharmacology German/Swiss Pharmaceutical Companies and a member of the Program Committee of the Safety Pharmacology Society.
Michael R. Gralinski, Ph.D. Chief Executive Officer, Co-Founder (CorDynamics). Mike is the Chief Executive Officer and Co-Founder of CorDynamics, a cardiovascular contract research organization and consulting group in Chicago. Along with his partners, Mike started CorDynamics in 2003 and since then the company has grown into a leading provider of nonclinical cardiovascular services for more than 300 international biopharmaceutical clients. Mike also has extensive management experience working for several pharmaceutical organizations including Warner-Lambert/Parke-Davis, G.D. Searle, Monsanto, Pharmacia, and Pfizer. His past responsibilities included directing product safety and toxicology operations, leading resolution efforts for cardiovascular issues involving discovery, development, and marketed compounds including Rezulin, Celebrex, and other COX-2 inhibitors, as well as cultivating relationships with international colleagues throughout small and large biopharma. He was involved in the genesis of the Safety Pharmacology Society and has been elected to multiple positions on its Board of Directors including Treasurer, Vice-President, and President. Mike earned his B.S. in Pharmacology & Toxicology at the University of Wisconsin-Madison and Ph.D. in Pharmacology at the University of Michigan.